• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Chugai Pharma - Articles and news items

Alecensa trial stopped early; meets primary endpoint

Industry news / 10 February 2016 / Victoria White

The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib…

NICE recommends RoActemra for severe rheumatoid arthritis

Industry news / 4 September 2015 / Victoria White

RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs…